SSKN
STRATA Skin Sciences, Inc.
Next earnings Aug 11, 2026 · consensus $-0.40 EPS, $8.23M rev
Last earnings -9.5% on 2025-11-13
$0.13
▲ 0.00%$0.13▼ -94.42%
over 1Y
L $0.12EODHDH $2.83
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W+7.4%
1M-7.1%
3M-50.0%
YTD-89.8%
1Y-94.4%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Revenue declined -8.5% YoY.
Revenue (FY2025) $30.7M · FY2025
STRATA Skin Sciences, Inc. shows $30.7M in FY2025 revenue (-8.5% YoY), a -20.4% net margin, and -210.2% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $30.0M | $36.2M | $33.4M | $33.6M | $30.7M |
| Gross profit | $19.9M | $21.8M | $18.5M | $19.2M | $17.9M |
| Operating income | -$4.40M | -$4.65M | -$8.60M | -$9.26M | -$4.70M |
| Net income | -$2.71M | -$5.55M | -$10.8M | -$10.1M | -$6.26M |
| Diluted EPS | — | -$0.16 | -$3.10 | -$2.65 | -$1.35 |
| Net margin | -9.0% | -15.3% | -32.5% | -30.1% | -20.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$8.20M
EV / EBITDA—
EV / Sales0.3
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-817.9%
FCF yield-556.8%
Quality & risk
ROIC (est.)-20.3%
Free cash flow-$4.26M
Total debt$15.3M
Net cash-$7.44M
Altman Z-Score-10.06 distress
Piotroski F-Score5/9
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+41.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — delisting notice (2026-02-11). Worth a closer look.
Recent filings
all on EDGAR ↗10-KPeriod ending 2025-12-312026-03-26open ↗EFFECTFiling2026-03-04open ↗EFFECTFiling2026-03-04open ↗EFFECTFiling2026-03-04open ↗15-12GFiling2026-03-02open ↗POS AMFiling2026-02-27open ↗POS AMFiling2026-02-27open ↗POS AMFiling2026-02-27open ↗S-8 POSFiling2026-02-27open ↗S-8 POSFiling2026-02-27open ↗S-8 POSFiling2026-02-27open ↗S-8 POSFiling2026-02-27open ↗
Frequently asked
- Is STRATA Skin Sciences, Inc. (SSKN) a buy?
- SSKN currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Revenue declined -8.5% YoY.
- What is STRATA Skin Sciences, Inc.'s quality score?
- SSKN scores 53.509803921568626/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001051514, latest 10-K filed 2026-03-26) · EODHD · as of 6/27/2026, 5:26:45 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.